Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

被引：5
|
作者：
Han, Ji Won [1 ,2 ]
Jang, Jeong Won [1 ,2 ]
机构：
[1] Catholic Univ Korea, Catholic Univ Liver Res Ctr, Coll Med, Seoul 06591, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Gastroenterol & Hepatol, Seoul 06591, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 14期
基金：
新加坡国家研究基金会;
关键词：
hepatocellular carcinoma; atezolizmumab-bevacizumab; biomarker; NEUTROPHIL-LYMPHOCYTE RATIO; PLUS BEVACIZUMAB; TUMOR; EXPRESSION; CELLS; INTERLEUKIN-6; MULTICENTER; COMBINATION; SUPPRESSION; SORAFENIB;
D O I：
10.3390/ijms241411799
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number of patients do not achieve survival or significant responses, indicating the need to identify predictive biomarkers for initial and on-treatment decisions in HCC patients receiving AB. In this manuscript, we summarized the current data from both experimental and clinical studies. This review will be beneficial for both clinicians and researchers in clinical practice as well as those designing experimental, translational, or clinical studies.
引用
收藏
页数：22
相关论文
共 50 条
  • [31] Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
    Suga, Takayoshi
    Kimura, Yuko
    Furuya, Kensuke
    Sato, Hiroko
    CLINICAL CASE REPORTS, 2023, 11 (09):
  • [32] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [33] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
    D'Alessio, Antonio
    Cammarota, Antonella
    Zanuso, Valentina
    Pressiani, Tiziana
    Personeni, Nicola
    Rimassa, Lorenza
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
  • [34] RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab
    Kim, Dong Hwan
    Min, Eun Jeong
    Kim, Bohyun
    Choi, Jong Young
    Jang, Jeong Won
    Sung, Pil Soo
    Han, Ji Won
    Kim, Hokun
    Choi, Joon-Il
    EUROPEAN RADIOLOGY, 2024, : 684 - 694
  • [35] Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series
    Kang, Wendi
    Fu, Hongjiang
    Luo, Yingen
    Noreika, Danielle M.
    Cong, Tianhao
    Li, Hang
    Yang, Zhengqiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 780 - 787
  • [36] The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
    Lieb, Sabine
    Ebel, Sebastian
    Seehofer, Daniel
    Berg, Thomas
    van Boemmel, Florian
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (01) : 148 - 150
  • [37] Efficacy and patient-report outcomes of atezolizumab/bevacizumab for unresectable hepatocellular carcinoma in Thailand
    Charonpongsuntorn, Chanchai
    Tanasanvimon, Suebpong
    Korphaisarn, Krittiya
    Payapwattanawong, Songwit
    Siripoon, Teerada
    Juengsamarn, Jitlada
    Phaibulvatanapong, Ekkamol
    Chindaprasirt, Jarin
    Prasongsook, Naiyarat
    Udomdamrongkul, Kittipong
    Pakvisal, Nussara
    Ngamphaiboon, Nuttapong
    Sirachainan, Ekaphop
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
  • [38] Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
    Fujimasa Tada
    Atsushi Hiraoka
    Toshifumi Tada
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Atsushi Naganuma
    Hisashi Kosaka
    Tomomitsu Matono
    Hidekatsu Kuroda
    Yutaka Yata
    Hideko Ohama
    Kazuhiro Nouso
    Asahiro Morishita
    Akemi Tsutsui
    Takuya Nagano
    Norio Itokawa
    Tomomi Okubo
    Taeang Arai
    Keisuke Yokohama
    Hiroki Nishikawa
    Michitaka Imai
    Yohei Koizumi
    Shinichiro Nakamura
    Hiroko Iijima
    Masaki Kaibori
    Yoichi Hiasa
    Takashi Kumada
    Journal of Gastroenterology, 2023, 58 : 1134 - 1143
  • [39] FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
    Casak, Sandra J.
    Donoghue, Martha
    Fashoyin-Aje, Lola
    Jiang, Xiaoping
    Rodriguez, Lisa
    Shen, Yuan-Li
    Xu, Yuan
    Jiang, Xiling
    Liu, Jiang
    Zhao, Hong
    Pierce, William F.
    Mehta, Shubhangi
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1836 - 1841
  • [40] The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients
    Aranda-Gutierrez, Alejandro
    Conde-Flores, Emilio
    Meraz-Brenez, Andres
    Escorza, Salvador
    Meneses-Medina, Monica I. Isabel
    Huitzil-Melendez, Fidel David
    de la Mora-Molina, Hector
    Rosas Camargo, Vanessa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345